

Trustees Report for 2025 Accounts

KF: NHS England meeting for Pembro for ATC pts
KF: Working party meeting for ION paper
KF: Letter for David Hamilton for thy3f patients
KF: Pembro meeting
KF: Thyroid group meeting NCRI
KF: Omar Hilmi funding discussion pt eye, suggest BTF part fund
KF: Call with Neil and Nikita re WTC Boston – BTCT to part fund Nikita's travel + subsistence. Nikita to be responsible for QR code cards and ensuring Molly's film shown on monitors at venue.
KF: New patient information film (Molly's film) accepted for WTC and Nikita to represent BTCT
KF: HOT Trial meeting
KF: Lauren Hullett
KF: Investigated showing new patient information film in Newcastle to a select audience
KF: Selpercatinib submission for SMC
KF: Individualisation of RAI room for Ollie at NCCC
SF: Preparation for "Rarity Life Magazine" article on BTCT
KF: HoT trial meeting
KF: Discussion with Amy Barnes (radiographer in Leicester) regarding AI support for U/S scans (basically underlining what we already know about KOIOS software.
KF: Mollys film to be shown at World Congress Boston and confirmed sponsorship of Dr Nikita Chander as BTCT representative. Nikita to be responsible for dissemination of new QR code cards to attendees.
KF: Facilitated patient with rare gene fusion for filming
KF: Facilitated support for Northampton patient who wasn't given any information at diagnosis
KF: Press release for ION
KF: BAETS webinar
KF: SMC submission and meeting for Selpercatinib
KF: Selpercatinib PACE meeting for Scotland
KF: NCRI meeting - discussion regarding whether 'fat jabs' were appropriate for thyroid cancer pts ?
KF: ION documents finalized
KF: New trial coming Dr Carlos Wong AI – BTCT offered to help with patient involvement and information

KF: Protracted NCRI meeting. Discussions include both national and international research trials.

KF: further discussion on GLP1 agonists and thyroid cancer pt information

KF: Press re ION trial results

KF: Family support for 9 year old with lung metastases

SF: Rarity Life Magazine article published

KF: First meeting for new generic pt info film to replace "Thyroid Cancer uncovered"

Niki Chander attended World CONGRESS with "My Thyroid and Me" young patient information film (Molly's film)

KF: Discussion regarding upgrades to paediatric rooms at The Christie and Glasgow

KF: Further work with Play Team at Christie to do paediatric rooms and also links for Glasgow established

KF: Mollys film to be broadcast on the BAETS APP for conference 2025

KF: Presentation for Imperial College patients

KF: meeting to discuss new nodule investigation guidelines

KF: Glasgow paediatric patient room

KF: Alicja's PHD project published in BMJ – "Factors affecting thyroid cancer survivors"

KF: further support for Balraj's family wrt ongoing treatment

KF: Discussion with Dr Carlos King Ho Wong regarding an AI development aid in thyroid cancer decision making

KF: NorthEast Enterprise Award

KF: Further discussions with Amy Barnes, Sheffield NIHR re. thyroid nodules AI to reduce number of FNAS

KF: Molly's film shortlisted for Smiley film awards

KF: Molly's film shortlisted for National TV film awards

KF: Meeting with Geroqe Mochloulis and Carian Cruz regarding thermal ablation vs surgery for micro carcinomas

Thermal Ablation v surgery for micropap ca

KF: Wanting multi centre study BTCT to support with patient group , me to be stakeholder ,they want NIHR grant .

KF: Meeting with Neil Sharma to discuss trial looking at surveillance vs surgery for low risk tc

AH: patient mediator offering support to patients on Thursdays through email, text, virtual meetings and telephone. Attends virtual and live meetings pertinent to her position in BTCT. Assists in local RAI room Individualisation for young patients.

SF: Administrator for BTCT, responsible for maintaining sufficient supplies of QR code cards, leaflets, stationery and advertising/ awareness supplies; liaising with national centres to deliver BTCT patient information media; accounts and finance; charity commission and HMRC governance; fundraising; IT; lodge bookings and maintenance; involvement in grant submissions and virtual meetings pertinent to his role.

Abbreviations:

KF	Kate Farnell
SF	Steven Farnell
AH	Amy Horton
EP	Euan Preston
BTCT	Butterfly Thyroid Cancer Trust
SMC	Scottish Medical Committee
NICE	National Institute for Clinical Excellence
D & T	Dabrafenib & Trametinib
TC	Thyroid Cancer
UCLH	University College London Hospitals
BAETS	British Association of Endocrine Thyroid Surgeons
ION	Iodine or Not
USS	Ultrasound Scan
PPI	Patient & Public Involvement
BTF	British Thyroid Foundation
BTA	British Thyroid Association
RAI	Radioactive Iodine Treatment
TYA	Teenage & Young Adult cancers
NuTH	Newcastle upon Tyne Hospitals charity
NIHR	National Institute for Health and Care Research
HOT	Hemi or Not
ATC	Advanced Thyroid Cancer
WTC	World Thyroid Cancer Congress
NCCC	Northern Cancer Care Centre
JW	Jon Wadsley
KG	Kate Garcez
KN	Kate Newbold
CRUK	Cancer Research UK

BUTTERFLY THYROID CANCER TRUST

Registered Charity number: 1108932

**FINANCIAL ACCOUNTS FOR THE
YEAR ENDED 31ST DECEMBER 2025**

DRAYCOTT & KIRK
CHARTERED CERTIFIED ACCOUNTANTS

92 Westgate
Guisborough
Cleveland
TS14 6AP

BUTTERFLY THYROID CANCER TRUST

SUPPORT GROUP INFORMATION
YEAR ENDED 31 DECEMBER 2025

Trustees:	Mr F Stafford F.R.C.S Mr J Salter Mr D Farnell Bsc Mrs D Golightly Mrs R Newton
Address	PO Box 205 Rowlands Gill Tyne & Wear NE39 2WX
Bankers	Lloyds TSB West Street Gateshead
Accountants	Draycott & Kirk LLP Chartered Certified Accountants Cleveland House 92 Westgate Guisborough CLEVELAND TS14 6AP
Reg. charity no.	1108932

Independent Examiner's Report to the Trustees of Butterfly Thyroid Cancer Trust

I report on the accounts of the charity for the year ended 31 December 2025 which are set out on pages 3 to 6

Respective responsibilities of trustees and examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

It is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a "true and fair view" and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

- 1 which gives me reasonable cause to believe that, in any material respect, the requirements:
 - to keep accounting records in accordance with section 130 of the 2011 Act; and
 - to prepare accounts which accord with the accounting records and comply with the accounting requirements of the 2011 Acthave not been met; or
- 2 to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



C N Mason

Chartered Certified Accountant

Draycott & Kirk LLP
Cleveland House
92 Westgate
Guisborough
Cleveland
TS14 6AP

Date 21 April 2026

BUTTERFLY THYROID CANCER TRUST
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31ST DECEMBER 2025

Registered charity number 1108932

Charity's principal address PO Box 205
Rowlands Gill
Tyne & Wear
NE39 2WX

Names of Charity trustees who manage the charity

Mr F Stafford F.R.C.S
Mrs D Golightly
Mr J Salter
Mr D Farnell Bsc
Mrs R Newton

Structure, governance and management

Governing document	Trust Deed
Constitution	Trust
Trustee selection methods	Trustees selected by existing Trustees

Objectives and activities

To alleviate the physical, psychological or financial difficulties or hardship of people affected by thyroid cancer.
To promote education about thyroid cancer to members of the public at large.
The charity provides:

A dedicated telephone helpline.	Holidays
A buddy system	Awareness Events
Patient information packs	Research Grants
Website	Patient information DVD
On site clinical support	Suppression cards
Hospital visits	Conference Presentations
Facilitates patient introductions	RAI room accessories
Attends thyroid cancer conferences	Clinical Trials advisory role
Network of patient support contacts	Patient information advisory role
RAI room renovations/revamp	QR Code cards
NICE TC commissioner – national TC guidelines	
Provision of holiday respite accommodation	
Patient Information Management position for Scottish Thyroid Cancer Network	

Volunteers and group members are involved in fund raising activities. They attend and provide information stands at relevant conferences.

BUTTERFLY THYROID CANCER TRUST
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31ST DECEMBER 2025

Summary of the main activities and achievements undertaken for the public benefit in relation to the objects

KF: NHS England meeting for Pembro for ATC pts
KF: Working party meeting for ION paper
KF: Letter for David Hamilton for thy3f patients
KF: Pembro meeting
KF: Thyroid group meeting NCRI
KF: Omar Hilmi funding discussion pt eye, suggest BTF part fund
KF: Call with Neil and Nikita re WTC Boston – BTCT to part fund Nikita's travel + subsistence. Nikita to be responsible for QR code cards and ensuring Molly's film shown on monitors at venue.
KF: New patient information film (Molly's film) accepted for WTC and Nikita to represent BTCT
KF: HOT Trial meeting
KF: Lauren Hullett
KF: Investigated showing new patient information film in Newcastle to a select audience
KF: Selpercatinib submission for SMC
KF: Individualisation of RAI room for Ollie at NCCC
SF: Preparation for "Rarity Life Magazine" article on BTCT
KF: HoT trial meeting
KF: Discussion with Amy Barnes (radiographer in Leicester) regarding AI support for U/S scans (basically underlining what we already know about KOIOS software).
KF: Mollys film to be shown at World Congress Boston and confirmed sponsorship of Dr Nikita Chander as BTCT representative. Nikita to be responsible for dissemination of new QR code cards to attendees.
KF: Facilitated patient with rare gene fusion for filming
KF: Facilitated support for Northampton patient who wasn't given any information at diagnosis
KF: Press release for ION
KF: BAETS webinar
KF: SMC submission and meeting for Selpercatinib
KF: Selpercatinib PACE meeting for Scotland
KF: NCRI meeting - discussion regarding whether 'fat jabs' were appropriate for thyroid cancer pts ?
KF: ION documents finalized
KF: New trial coming Dr Carlos Wong AI – BTCT offered to help with patient involvement and information

KF: Protracted NCRI meeting. Discussions include both national and international research trials.

KF: further discussion on GLP1 agonists and thyroid cancer pt information
KF: Press re ION trial results
KF: Family support for 9 year old with lung metastases
SF: Rarity Life Magazine article published
KF: First meeting for new generic pt info film to replace "Thyroid Cancer uncovered"
Niki Chander attended World CONGRESS with "My Thyroid and Me" young patient information film (Molly's film)
KF: Discussion regarding upgrades to paediatric rooms at The Christie and Glasgow
KF: Further work with Play Team at Christie to do paediatric rooms and also links for Glasgow established
KF: Mollys film to be broadcast on the BAETS APP for conference 2025
KF: Presentation for Imperial College patients
KF: meeting to discuss new nodule investigation guidelines
KF: Glasgow paediatric patient room
KF: Alicja's PHD project published in BMJ – "Factors affecting thyroid cancer survivors"
KF: further support for Balraj's family wrt ongoing treatment
KF: Discussion with Dr Carlos King Ho Wong regarding an AI development aid in thyroid cancer decision making
KF: NorthEast Enterprise Award
KF: Further discussions with Amy Barnes, Sheffield NIHR re. thyroid nodules AI to reduce number of FNAS
KF: Molly's film shortlisted for Smiley film awards
KF: Molly's film shortlisted for National TV film awards

KF: Meeting with Gerge Mochloulis and Carian Cruz regarding thermal ablation vs surgery for micro carcinomas

KF: Wanting multi centre study BTCT to support with patient group , me to be stakeholder ,they want NIHR grant .

KF: Meeting with Neil Sharma to discuss trial looking at surveillance vs surgery for low risk tc

BUTTERFLY THYROID CANCER TRUST
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31ST DECEMBER 2025

Summary of the main activities and achievements undertaken for the public benefit in relation to the objects continued...

AH: patient mediator offering support to patients on Thursdays through email, text, virtual meetings and telephone. Attends virtual and live meetings pertinent to her position in BTCT. Assists in local RAI room Individualisation for young patients.

SF: Administrator for BTCT, responsible for maintaining sufficient supplies of QR code cards, leaflets, stationery and advertising/ awareness supplies; liaising with national centres to deliver BTCT patient information media; accounts and finance; charity commission and HMRC governance; fundraising; IT; lodge bookings and maintenance; involvement in grant submissions and virtual meetings pertinent to his role.

Abbreviations:

KF	Kate Farnell
SF	Steven Farnell
AH	Amy Horton
EP	Euan Preston
BTCT	Butterfly Thyroid Cancer Trust
SMC	Scottish Medical Committee
NICE	National Institute for Clinical Excellence
D & T	Dabrafenib & Trametinib
TC	Thyroid Cancer
UCLH	University College London Hospitals
BAETS	British Association of Endocrine Thyroid Surgeons
ION	Iodine or Not
USS	Ultrasound Scan
PPI	Patient & Public Involvement
BTF	British Thyroid Foundation
BTA	British Thyroid Association
RAI	Radioactive Iodine Treatment
TYA	Teenage & Young Adult cancers
NuTH	Newcastle upon Tyne Hospitals charity
NIHR	National Institute for Health and Care Research
HOT	Hemi or Not
ATC	Advanced Thyroid Cancer
WTC	World Thyroid Cancer Congress
NCCC	Northern Cancer Care Centre
JW	Jon Wadsley
KG	Kate Garcez
KN	Kate Newbold
CRUK	Cancer Research UK

BUTTERFLY THYROID CANCER TRUST

TRUSTEES ANNUAL REPORT

FOR THE YEAR ENDED 31ST DECEMBER 2025

Reserve Policy

Designated funds:

£10,000 - Butterfly Lodge

£7,500 - Patient support contact

£15,000 - PHD support for research project investigating AI in ultrasound scanning of thyroid gland - Leicester University.

£25,000 - designated to administrative costs.

£350,000 in fixed term savings accounts.

£266,000 in 95 day notice savings account

Balance of the reserves to sustain present and future projects

Review of financial Position at year end.

Considered the position to be satisfactory.

Signature 
Full Name Daniel Farnell
Position Trustee
Dated 18.4.26

BUTTERFLY THYROID CANCER TRUST

Statement of financial affairs for the year to 31 December 2025

	Note	Unrestricted Funds	Restricted Funds	Designated Funds	Total Funds	2024
Incoming Resources						
Grants	2	50,000	-	-	50,000	70,000
Donations		78,512	-	-	78,512	202,298
Gift Aid		1,183	-	-	1,183	1,614
Deposit account interest		13,199	-	-	13,199	17,134
Total Incoming Resources		142,894	-	-	142,894	291,046
Expenditure						
Direct charitable expenditure						
Payroll		72,648	-	-	72,648	71,226
Professional fees		43,035	-	-	43,035	31,908
Telephone		1,453	-	-	1,453	2,013
Postage and stationery		1,377	-	-	1,377	1,706
Insurance		738	-	-	738	805
Advertising		2,866	-	-	2,866	3,424
Motor & travelling costs		8,841	-	-	8,841	1,867
Repairs and maintenance		505	-	-	505	367
Sundries		2,280	-	-	2,230	1,508
Awards		-	-	-	-	437
Grants	2	599	-	-	599	8,400
Information film		288	-	-	238	7,920
Holiday Lodge Costs		6,655	-	-	6,655	5,826
Conferences		1,966	-	-	1,936	86
Phd Sponsorship	2	-	-	-	-	7,930
Accountancy		480	-	-	430	450
Profit on disposal of asset		-	-	-	-	-
Depreciation		23,690	-	-	23,690	27,360
Total Expenditure		167,421	-	-	167,421	173,233
Transfers between funds						
Net Incoming/Outgoing Resources		(24,527)	-	-	(24,527)	117,813
Total funds brought forward		791,307	-	87,428	878,735	760,922
Total funds carried forward		766,780	-	87,428	854,208	878,735

BUTTERFLY THYROID CANCER TRUST
BALANCE SHEET AS AT 31ST DECEMBER 2025

	<u>NOTE</u>	<u>2025</u>		<u>2024</u>	
		£	£	£	£
<u>FIXED ASSETS</u>					
Land & buildings	3		130,050		153,000
Fixtures & equipment	3		3,469		1,677
<u>CURRENT ASSETS</u>					
Debtors			-		-
Bank Accounts		720,092		723,461	
Cash In Hand		597	720,689	597	724,058
			854,208		878,735
<u>CURRENT LIABILITIES</u>					
			-		-
<u>NET ASSETS</u>	3		854,208		878,735
<u>FUNDS</u>					
Restricted Funds	4		-		-
Unrestricted Funds	4		766,730		791,307
Designated funds	4		87,428		87,428
			854,208		878,735

These Financial Statements were approved by the Trustees on

Date 18.4.26

Signed 

Full Name Daniel Farnell

Trustee

BUTTERFLY THYROID CANCER TRUST

Notes to the Accounts for the period ended 31st December 2025

1 Accounting Policies

- a. The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance Accounting and Reporting by Charities: Statement of Recommended practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 (as updated through update bulletin 1 published on 2 February 2016), the Financial Reporting Standards applicable in the United Kingdom and Republic of Ireland (FRS 102) and UK Generally accepted practice as it applies from 1 January 2015.
- The charity has applied update bulletin 1 as published on 2 February 2016 and does not include a cash flow statement on the grounds it is applying FRS 102 Section 1A.
- The Financial statements are prepared on a going concern basis under the historical cost convention. The Financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest pound.
- The significant accounting policy's applied in the preparation of the financial statements are set out below. These policies have been applied to all years shown unless otherwise stated.
- b. **Funds**
- Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.
- Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the accounts.
- c. All grants and voluntary income are accounted for gross when receivable, as long as they are capable of financial measurement.
- d. All expenditure is accounted for gross of VAT, and when incurred.
- e. Provision for depreciation of fixed assets held for use by the charity is made at annual rates calculated to spread the cost (less anticipated residual disposable value) of each asset evenly over its expected useful life. The depreciation rates currently in use for fixed assets held for use by the charity are 15% on straight line for Fixtures and equipment and 15% reducing balance for land and buildings.
- f. Reserves policy: The trustees have considered the level of reserves needed in order to maintain the ongoing activities of the charity. The trustees consider that an amount representing twelve months running costs are advisable.

2a Grants Receivable

	<u>2025</u>	<u>2024</u>
	£	£
Syncona	50,000	70,000
	-	-
	<u>50,000</u>	<u>70,000</u>

Details of grants are included in note 4.

BUTTERFLY THYROID CANCER TRUST

Notes to the Accounts for the period ended 31st December 2025

2b Grants made

	£
Research Grant - University of Sheffield	-
Improvements to RAI rooms	599
	<u>599</u>

3 Tangible Fixed Assets

	<u>Fixtures & Equipment</u>	<u>Holiday Lodge</u>	<u>Total</u>
B/f	2,397	180,000	182,397
Additions during the period	<u>2,532</u>	<u>-</u>	<u>2,532</u>
	4,929	180,000	184,929
Depreciation B/f	720	27,000	27,720
Depreciation for the year	<u>740</u>	<u>22,950</u>	<u>23,690</u>
Depreciation C/f	1,460	49,950	51,410
Net book value at 31 December 2025	<u>3,469</u>	<u>130,050</u>	<u>133,519</u>

4 Funds

	<u>Opening balance</u>	<u>Incoming resources</u>	<u>Transfer between funds</u>	<u>Outgoing resources</u>	<u>Closing balance</u>
Unrestricted funds	791,307	142,894	-	(167,421)	766,780
Restricted funds	-	-	-	-	-
Designated Funds	a) 87,428	-	-	-	87,428

a) Donations from Syncona to be used for Research Grant Award, holiday lodge and hospital improvements, but not exclusively

5 Analysis of funds by assets

	Unrestricted	Restricted	Designated	Total
Fixed assets	133,519	-	-	133,519
Current assets	633,261	-	87,428	720,639
Current liabilities	-	-	-	-
	<u>766,780</u>	<u>-</u>	<u>87,428</u>	<u>854,208</u>

6 Transactions with trustee's and connected persons

During the year there was no transactions with Trustees or connected persons including remuneration or expenses.

7 Trustee indemnity insurance

During the year, insurance was purchased to indemnify the committee against default on their part.

8 Control

The charity is under the control of the Trustees.

BUTTERFLY THYROID CANCER TRUST

Registered Charity number: 1108932

**FINANCIAL ACCOUNTS FOR THE
YEAR ENDED 31ST DECEMBER 2025**

DRAYCOTT & KIRK
CHARTERED CERTIFIED ACCOUNTANTS
92 Westgate
Guisborough
Cleveland
TS14 6AP

BUTTERFLY THYROID CANCER TRUST

SUPPORT GROUP INFORMATION
YEAR ENDED 31 DECEMBER 2025

Trustees:	Mr F Stafford F.R.C.S Mr J Salter Mr D Farnell Bsc Mrs D Golightly Mrs R Newton
Address	PO Box 205 Rowlands Gill Tyne & Wear NE39 2WX
Bankers	Lloyds TSB West Street Gateshead
Accountants	Draycott & Kirk LLP Chartered Certified Accountants Cleveland House 92 Westgate Guisborough CLEVELAND TS14 6AP
Reg. charity no.	1108932

Independent Examiner's Report to the Trustees of Butterfly Thyroid Cancer Trust

I report on the accounts of the charity for the year ended 31 December 2025 which are set out on pages 3 to 6

Respective responsibilities of trustees and examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

It is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a "true and fair view" and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

- 1 which gives me reasonable cause to believe that, in any material respect, the requirements:
 - to keep accounting records in accordance with section 130 of the 2011 Act; and
 - to prepare accounts which accord with the accounting records and comply with the accounting requirements of the 2011 Acthave not been met; or
- 2 to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



C N Mason

Chartered Certified Accountant

Draycott & Kirk LLP
Cleveland House
92 Westgate
Guisborough
Cleveland
TS14 6AP

Date 21 April 2026

BUTTERFLY THYROID CANCER TRUST
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31ST DECEMBER 2025

Registered charity number 1108932

Charity's principal address PO Box 205
Rowlands Gill
Tyne & Wear
NE39 2WX

Names of Charity trustees who manage the charity

Mr F Stafford F.R.C.S
Mrs D Golightly
Mr J Salter
Mr D Farnell Bsc
Mrs R Newton

Structure, governance and management

Governing document	Trust Deed
Constitution	Trust
Trustee selection methods	Trustees selected by existing Trustees

Objectives and activities

To alleviate the physical, psychological or financial difficulties or hardship of people affected by thyroid cancer.
To promote education about thyroid cancer to members of the public at large.
The charity provides:

A dedicated telephone helpline.	Holidays
A buddy system	Awareness Events
Patient information packs	Research Grants
Website	Patient information DVD
On site clinical support	Suppression cards
Hospital visits	Conference Presentations
Facilitates patient introductions	RAI room accessories
Attends thyroid cancer conferences	Clinical Trials advisory role
Network of patient support contacts	Patient information advisory role
RAI room renovations/revamp	QR Code cards
NICE TC commissioner – national TC guidelines	
Provision of holiday respite accommodation	
Patient Information Management position for Scottish Thyroid Cancer Network	

Volunteers and group members are involved in fund raising activities. They attend and provide information stands at relevant conferences.

BUTTERFLY THYROID CANCER TRUST
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31ST DECEMBER 2025

Summary of the main activities and achievements undertaken for the public benefit in relation to the objects

KF: NHS England meeting for Pembro for ATC pts
KF: Working party meeting for ION paper
KF: Letter for David Hamilton for thy3f patients
KF: Pembro meeting
KF: Thyroid group meeting NCRI
KF: Omar Hilmi funding discussion pt eye, suggest BTF part fund
KF: Call with Neil and Nikita re WTC Boston – BTCT to part fund Nikita's travel + subsistence. Nikita to be responsible for QR code cards and ensuring Molly's film shown on monitors at venue.
KF: New patient information film (Molly's film) accepted for WTC and Nikita to represent BTCT
KF: HOT Trial meeting
KF: Lauren Hullett
KF: Investigated showing new patient information film in Newcastle to a select audience
KF: Selpercatinib submission for SMC
KF: Individualisation of RAI room for Ollie at NCCC
SF: Preparation for "Rarity Life Magazine" article on BTCT
KF: HoT trial meeting
KF: Discussion with Amy Barnes (radiographer in Leicester) regarding AI support for U/S scans (basically underlining what we already know about KOIOS software).
KF: Mollys film to be shown at World Congress Boston and confirmed sponsorship of Dr Nikita Chander as BTCT representative. Nikita to be responsible for dissemination of new QR code cards to attendees.
KF: Facilitated patient with rare gene fusion for filming
KF: Facilitated support for Northampton patient who wasn't given any information at diagnosis
KF: Press release for ION
KF: BAETS webinar
KF: SMC submission and meeting for Selpercatinib
KF: Selpercatinib PACE meeting for Scotland
KF: NCRI meeting - discussion regarding whether 'fat jabs' were appropriate for thyroid cancer pts ?
KF: ION documents finalized
KF: New trial coming Dr Carlos Wong AI – BTCT offered to help with patient involvement and information

KF: Protracted NCRI meeting. Discussions include both national and international research trials.

KF: further discussion on GLP1 agonists and thyroid cancer pt information
KF: Press re ION trial results
KF: Family support for 9 year old with lung metastases
SF: Rarity Life Magazine article published
KF: First meeting for new generic pt info film to replace "Thyroid Cancer uncovered"
Niki Chander attended World CONGRESS with "My Thyroid and Me" young patient information film (Molly's film)
KF: Discussion regarding upgrades to paediatric rooms at The Christie and Glasgow
KF: Further work with Play Team at Christie to do paediatric rooms and also links for Glasgow established
KF: Mollys film to be broadcast on the BAETS APP for conference 2025
KF: Presentation for Imperial College patients
KF: meeting to discuss new nodule investigation guidelines
KF: Glasgow paediatric patient room
KF: Alicja's PHD project published in BMJ – "Factors affecting thyroid cancer survivors"
KF: further support for Balraj's family wrt ongoing treatment
KF: Discussion with Dr Carlos King Ho Wong regarding an AI development aid in thyroid cancer decision making
KF: NorthEast Enterprise Award
KF: Further discussions with Amy Barnes, Sheffield NIHR re. thyroid nodules AI to reduce number of FNAS
KF: Molly's film shortlisted for Smiley film awards
KF: Molly's film shortlisted for National TV film awards

KF: Meeting with Gerge Mochloulis and Carian Cruz regarding thermal ablation vs surgery for micro carcinomas

KF: Wanting multi centre study BTCT to support with patient group , me to be stakeholder ,they want NIHR grant .

KF: Meeting with Neil Sharma to discuss trial looking at surveillance vs surgery for low risk tc

BUTTERFLY THYROID CANCER TRUST
TRUSTEES ANNUAL REPORT
FOR THE YEAR ENDED 31ST DECEMBER 2025

Summary of the main activities and achievements undertaken for the public benefit in relation to the objects continued...

AH: patient mediator offering support to patients on Thursdays through email, text, virtual meetings and telephone. Attends virtual and live meetings pertinent to her position in BTCT. Assists in local RAI room Individualisation for young patients.

SF: Administrator for BTCT, responsible for maintaining sufficient supplies of QR code cards, leaflets, stationery and advertising/ awareness supplies; liaising with national centres to deliver BTCT patient information media; accounts and finance; charity commission and HMRC governance; fundraising; IT; lodge bookings and maintenance; involvement in grant submissions and virtual meetings pertinent to his role.

Abbreviations:

KF	Kate Farnell
SF	Steven Farnell
AH	Amy Horton
EP	Euan Preston
BTCT	Butterfly Thyroid Cancer Trust
SMC	Scottish Medical Committee
NICE	National Institute for Clinical Excellence
D & T	Dabrafenib & Trametinib
TC	Thyroid Cancer
UCLH	University College London Hospitals
BAETS	British Association of Endocrine Thyroid Surgeons
ION	Iodine or Not
USS	Ultrasound Scan
PPI	Patient & Public Involvement
BTF	British Thyroid Foundation
BTA	British Thyroid Association
RAI	Radioactive Iodine Treatment
TYA	Teenage & Young Adult cancers
NuTH	Newcastle upon Tyne Hospitals charity
NIHR	National Institute for Health and Care Research
HOT	Hemi or Not
ATC	Advanced Thyroid Cancer
WTC	World Thyroid Cancer Congress
NCCC	Northern Cancer Care Centre
JW	Jon Wadsley
KG	Kate Garcez
KN	Kate Newbold
CRUK	Cancer Research UK

BUTTERFLY THYROID CANCER TRUST

TRUSTEES ANNUAL REPORT

FOR THE YEAR ENDED 31ST DECEMBER 2025

Reserve Policy

Designated funds:

£10,000 - Butterfly Lodge

£7,500 - Patient support contact

£15,000 - PHD support for research project investigating AI in ultrasound scanning of thyroid gland - Leicester University.

£25,000 - designated to administrative costs.

£350,000 in fixed term savings accounts.

£266,000 in 95 day notice savings account

Balance of the reserves to sustain present and future projects

Review of financial Position at year end.

Considered the position to be satisfactory.

Signature 
Full Name Daniel Farnell
Position Trustee
Dated 18.4.26

BUTTERFLY THYROID CANCER TRUST

Statement of financial affairs for the year to 31 December 2025

	<u>Note</u>	<u>Unrestricted</u>	<u>Restricted</u>	<u>Designated</u>	<u>Total</u>	
		<u>Funds</u>	<u>Funds</u>	<u>Funds</u>	<u>Funds</u>	<u>2024</u>
<u>Incoming Resources</u>						
Grants	2	50,000	-	-	50,000	70,000
Donations		78,512	-	-	78,512	202,298
Gift Aid		1,183	-	-	1,183	1,614
Deposit account interest		13,199	-	-	13,199	17,134
<u>Total Incoming Resources</u>		142,894	-	-	142,894	291,046
<u>Expenditure</u>						
Direct charitable expenditure						
Payroll		72,648	-	-	72,648	71,226
Professional fees		43,035	-	-	43,035	31,908
Telephone		1,453	-	-	1,453	2,013
Postage and stationery		1,377	-	-	1,377	1,706
Insurance		738	-	-	738	805
Advertising		2,866	-	-	2,866	3,424
Motor & travelling costs		8,841	-	-	8,841	1,867
Repairs and maintenance		505	-	-	505	367
Sundries		2,280	-	-	2,230	1,508
Awards		-	-	-	-	437
Grants	2	599	-	-	599	8,400
Information film		288	-	-	238	7,920
Holiday Lodge Costs		6,655	-	-	6,655	5,826
Conferences		1,966	-	-	1,936	86
Phd Sponsorship	2	-	-	-	-	7,930
Accountancy		480	-	-	430	450
Profit on disposal of asset		-	-	-	-	-
Depreciation		23,690	-	-	23,690	27,360
<u>Total Expenditure</u>		167,421	-	-	167,421	173,233
<u>Transfers between funds</u>						
Net Incoming/Outgoing Resources		(24,527)	-	-	(24,527)	117,813
Total funds brought forward		791,307	-	87,428	878,735	760,922
Total funds carried forward		766,780	-	87,428	854,208	878,735

BUTTERFLY THYROID CANCER TRUST
BALANCE SHEET AS AT 31ST DECEMBER 2025

	<u>NOTE</u>	<u>2025</u>		<u>2024</u>	
		£	£	£	£
<u>FIXED ASSETS</u>					
Land & buildings	3		130,050		153,000
Fixtures & equipment	3		3,469		1,677
<u>CURRENT ASSETS</u>					
Debtors			-		-
Bank Accounts		720,092		723,461	
Cash In Hand		597	720,689	597	724,058
			854,208		878,735
<u>CURRENT LIABILITIES</u>					
			-		-
<u>NET ASSETS</u>	3		854,208		878,735
<u>FUNDS</u>					
Restricted Funds	4		-		-
Unrestricted Funds	4		766,730		791,307
Designated funds	4		87,428		87,428
			854,208		878,735

These Financial Statements were approved by the Trustees on

Date 18.4.26

Signed 

Full Name Daniel Farnell

Trustee

BUTTERFLY THYROID CANCER TRUST

Notes to the Accounts for the period ended 31st December 2025

1 Accounting Policies

- a. The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance Accounting and Reporting by Charities: Statement of Recommended practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 (as updated through update bulletin 1 publish on 2 February 2016), the Financial Reporting Standards applicable in the United Kingdom and Republic of Ireland (FRS 102) and UK Generally accepted practice as it applies from 1 January 2015.
- The charity has applied update bulletin 1 as published on 2 February 2016 and does not include a cash flow statement on the grounds it is applying FRS 102 Section 1A.
- The Financial statements are prepared on a going concern basis under the historical cost convention. The Financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest pound.
- The significant accounting policy's applied in the preparation of the financial statements are set out below. These policies have been applied to all years shown unless otherwise stated.
- b. **Funds**
- Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.
- Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the accounts.
- c. All grants and voluntary income are accounted for gross when receivable, as long as they are capable of financial measurement.
- d. All expenditure is accounted for gross of VAT, and when incurred.
- e. Provision for depreciation of fixed assets held for use by the charity is made at annual rates calculated to spread the cost (less anticipated residual disposable value) of each asset evenly over its expected useful life. The depreciation rates currently in use for fixed assets held for use by the charity are 15% on straight line for Fixtures and equipment and 15% reducing balance for land and buildings.
- f. Reserves policy: The trustees have considered the level of reserves needed in order to maintain the ongoing activities of the charity. The trustees consider that an amount representing twelve months running costs are advisable.

2a Grants Receivable

	<u>2025</u>	<u>2024</u>
	£	£
Syncona	50,000	70,000
	-	-
	<u>50,000</u>	<u>70,000</u>

Details of grants are included in note 4.

BUTTERFLY THYROID CANCER TRUST

Notes to the Accounts for the period ended 31st December 2025

2b Grants made

	£
Research Grant - University of Sheffield	-
Improvements to RAI rooms	599
	<u>599</u>

3 Tangible Fixed Assets

	<u>Fixtures & Equipment</u>	<u>Holiday Lodge</u>	<u>Total</u>
B/f	2,397	180,000	182,397
Additions during the period	<u>2,532</u>	<u>-</u>	<u>2,532</u>
	4,929	180,000	184,929
Depreciation B/f	720	27,000	27,720
Depreciation for the year	<u>740</u>	<u>22,950</u>	<u>23,690</u>
Depreciation C/f	1,460	49,950	51,410
Net book value at 31 December 2025	<u>3,469</u>	<u>130,050</u>	<u>133,519</u>

4 Funds

	<u>Opening balance</u>	<u>Incoming resources</u>	<u>Transfer between funds</u>	<u>Outgoing resources</u>	<u>Closing balance</u>
Unrestricted funds	791,307	142,894	-	(167,421)	766,780
Restricted funds	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Designated Funds	a) 87,428	-	-	-	87,428

a) Donations from Syncona to be used for Research Grant Award, holiday lodge and hospital improvements, but not exclusively

5 Analysis of funds by assets

	Unrestricted	Restricted	Designated	Total
Fixed assets	133,519	-	-	133,519
Current assets	633,261	-	87,428	720,639
Current liabilities	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
	766,780	-	87,428	854,208

6 Transactions with trustee's and connected persons

During the year there was no transactions with Trustees or connected persons including remuneration or expenses.

7 Trustee indemnity insurance

During the year, insurance was purchased to indemnify the committee against default on their part.

8 Control

The charity is under the control of the Trustees.